Dr. Luzum’s long-term goal is to reduce racial disparities and improve pharmacologic outcomes in patients with cardiovascular disease, particularly heart failure. She works to accomplish that goal using a variety of clinical & translational research approaches. Her recent work includes the discovery and validation of genetic polymorphisms affecting the efficacy and adverse effects of beta-blockers and statins. Her current research interests include the discovery of effective pharmacotherapy for patients with heart failure and preserved ejection fraction; a condition that affects millions of Americans and for which there is no known effective pharmacotherapy. Dr. Luzum also investigates and advocates pharmacogenomic clinical education and implementation. She was highly involved in the Translational Pharmacogenetics Project (TPP) within the PGRN, which collected and summarized the outcomes and metrics of clinical implementations of pharmacogenetics at several PGRN sites. In addition to her research, Dr. Luzum is a board-certified pharmacotherapy specialist and applied pharmacologist, and she has taken care of patients with cardiovascular disease in a variety of clinical settings.